Epidemiology and phenotypes of multiple sclerosis in the Middle East North Africa (MENA) region

Yamout, Bassem; Assaad, Wassim; Tamim, Hani; Mrabet, S.; Goueider, R.

doi:10.1177/2055217319841881

Cited by 38 publications

(39 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The United States validated a case-ascertainment algorithm and reported an almost doubling of prevalent cases to 913,925 in 2019. 5 An increasing prevalence of MS has also been reported across the Middle East and North African region, 6 in the Russian Federation, 7 Canada, 8 Australia 9 and in several European countries (Denmark, Germany, Poland, the United Kingdom). The Global Burden of Disease (GBD) 2016 Multiple Sclerosis Collaborators similarly reported that the prevalence of MS had risen between 1990 and 2016, estimating that there were 2,221,188 (95% Uncertainty Interval 2,033,866–2,436,858) persons living with MS in 2016.…”

Section: Resultsmentioning

confidence: 99%

“…. 5 An increasing prevalence of MS has also been reported across the Middle East and North African region, 6 in the Russian Federation, 7 Canada, 10 The GBD group relied on information in the literature, and modelling to generate estimates, and the updated United States prevalence figures used in the present Atlas which showed an increase of over 400,000 Americans living with MS were not available at that time.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

et al. 2020

View full text Add to dashboard Cite

Background: High-quality epidemiologic data worldwide are needed to improve our understanding of disease risk, support health policy to meet the diverse needs of people with multiple sclerosis (MS) and support advocacy efforts. Objectives: The Atlas of MS is an open-source global compendium of data regarding the epidemiology of MS and the availability of resources for people with MS reported at country, regional and global levels. Methods: Country representatives reported epidemiologic data and their sources via survey between September 2019 and March 2020, covering prevalence and incidence in males, females and children, and age and MS type at diagnosis. Regional analyses and comparisons with 2013 data were conducted. Results: A total of 2.8 million people are estimated to live with MS worldwide (35.9 per 100,000 population). MS prevalence has increased in every world region since 2013 but gaps in prevalence estimates persist. The pooled incidence rate across 75 reporting countries is 2.1 per 100,000 persons/year, and the mean age of diagnosis is 32 years. Females are twice as likely to live with MS as males. Conclusions: The global prevalence of MS has risen since 2013, but good surveillance data is not universal. Action is needed by multiple stakeholders to close knowledge gaps.

show abstract

Section: Resultsmentioning

confidence: 99%

mentioning

confidence: 99%

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Also, this nding could justify the high heterogeneity between studies, at least in part. Relevantly, other metaanalysis indicated different FMS prevalence in Iran (8.9%) [63] and the Middle East North Africa region (17.8%) [64].…”

Section: Discussionmentioning

confidence: 87%

The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis

Ehtesham

Rafie

Mosallaei

2021

Preprint

View full text Add to dashboard Cite

Background: Considering that familial multiple sclerosis (FMS) can reveal the extent to which genetic and environmental factors each involve in the etiopathogenesis of the disease, we performed an updated meta-analysis of the worldwide prevalence of FMS by addition of recent publications. Methods: A search in PubMed, Scopus, the ISI Web of Science, and Google Scholar up to 20 December 2020 was done. The inclusion criteria were based on the CoCoPop approach (condition, context, and population). The qualified studies entered the process of the meta-analysis by using comprehensive meta-analysis ver. 2 software.Results: The pooled prevalence of MS in relatives of 16179 FMS cases was estimated to be 11.8% (95% CI: 10.7-13) based on a random-effects model. The pooled mean age of disease onset in adult probands was calculated to be 28.7 years (95% CI: 27.2± 30.2). In 13 studies that reported the data of FMS in pediatrics (n=6636) and adults (n=877), the FMS prevalence was 10.8% (95% CI: 8.1-14.2) and 15.5% (95% CI: 13.8-17.4), respectively. Considering the data of 9 studies, the prevalence of FMS in males (n=5243) and females (n=11503) patients was calculated to be 13.7% (95% CI: 10.1-18.2) and 15.4% (95% CI: 10.3-22.4), respectively. The odds ratio of male/female in FMS cases was not statistically significant (OR= 0.9; 95% CI: 0.6-1.2, P=0.55). Subgroup analysis demonstrated a significant difference in the prevalence of FMS between the geographical areas (P= 0.007). The meta-regression model for FMS prevalence was significantly lower in terms of higher latitude (P< 0.001) and increased MS prevalence (P< 0.001). In contrast, meta-regression based on prevalence day was not statistically significant (P=0.29).Conclusions: The prevalence of FMS is more in the pediatric group than that of adults, is distinct between geographical areas, and diminishes with the increment of MS prevalence and latitude. Also, the symptoms initiate relatively at lower ages in FMS cases. By contrast with multifactorial diseases, our analysis unveiled that the prevalence of FMS was not more prevalent in men than women and the risk of MS development in relatives was not more when the affected proband was male.

show abstract

“…(AlJumah et al, 2020) In Lebanon, Yamout and colleagues found a high female/ male ratio of approximately 3. (Yamout et al, 2020). A number of previous studies have reported that 0.4-5.6% of MS patients have their onset of symptoms before the age of 16.…”

Section: Resultsmentioning

confidence: 99%

Profile of patients with Multiple sclerosis in Mosul City

Mohammed¹,

Alallaf²

2019

MJN

View full text Add to dashboard Cite

Background: This study was carried out to assess the prevalence of MS in Mosul City. Methods: A retrospective study was applied in Mosul City for the period between (2020-2000). MS patient's outpatient of Ibn-Sina Teaching hospital in Mosul City. Assessment of MS status: for the assessment of MS status the Kurtzke EDSS was used. EDSS was based on ten scores (0-10) and categorized the MS severity into three level; mild disability (EDSS, 0.0 to 3.5), moderate disability (EDSS, 4.0 to 6.5), and severe disability (EDSS, 7.0 to 9.5). Microsoft Excel file was used to analyzed the data, number, percentage, Mean and Standard deviation were computed analyze all demographic and clinical variables. This study was approved by the Ethics Committee of the Mosul Health Directorate, at Mosul City-Iraq. Results: the study found that the mean age of patients (34.7) among men and (32.9) among women. The mean age at onset is (28.9) among men and 27.9 among women. In relation to family history 89.8% of men and 93.9% of women don't have positive family history with MS. The majority of patent have Relapsing-remitting. Conclusion: In conclusion, the prevalence of MS has been steadily rising in the Mosul city over the past few decades.

show abstract

Epidemiology and phenotypes of multiple sclerosis in the Middle East North Africa (MENA) region

Cited by 38 publications

References 30 publications

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

Rising prevalence of multiple sclerosis worldwide: Insights from the Atlas of MS, third edition

The global prevalence of familial multiple sclerosis: an updated systematic review and meta-analysis

Profile of patients with Multiple sclerosis in Mosul City

Contact Info

Product

Resources

About